12:00 AM
 | 
Mar 25, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Iclusig ponatinib regulatory update

EMA's CHMP issued a positive opinion recommending approval of an MAA for Iclusig ponatinib from Ariad to treat chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Iclusig is recommended to treat chronic, accelerated or blast phase CML that is resistant to or intolerant of nilotinib...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >